Jennifer Lynn Guerriero, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Macrophages | 8 | 2024 | 5737 | 1.070 |
Why?
|
Tumor Microenvironment | 17 | 2024 | 3840 | 1.040 |
Why?
|
Receptors, Progesterone | 3 | 2021 | 1130 | 0.680 |
Why?
|
Neovascularization, Pathologic | 2 | 2021 | 2638 | 0.650 |
Why?
|
Mammary Neoplasms, Experimental | 1 | 2021 | 507 | 0.630 |
Why?
|
Neoplasms, Experimental | 3 | 2020 | 1228 | 0.600 |
Why?
|
Breast Neoplasms | 10 | 2024 | 21017 | 0.590 |
Why?
|
Histone Deacetylase Inhibitors | 3 | 2021 | 772 | 0.520 |
Why?
|
Antineoplastic Agents, Alkylating | 2 | 2011 | 617 | 0.520 |
Why?
|
Receptors, Estrogen | 3 | 2024 | 2211 | 0.480 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 7 | 2021 | 1086 | 0.470 |
Why?
|
Receptor, erbB-2 | 3 | 2023 | 2553 | 0.460 |
Why?
|
Immunotherapy | 7 | 2024 | 4641 | 0.400 |
Why?
|
Immune Tolerance | 1 | 2021 | 2297 | 0.400 |
Why?
|
Cell Line, Tumor | 15 | 2024 | 16886 | 0.370 |
Why?
|
Drug Resistance, Neoplasm | 7 | 2021 | 5248 | 0.350 |
Why?
|
HMGB1 Protein | 1 | 2011 | 137 | 0.340 |
Why?
|
Glioblastoma | 1 | 2023 | 3480 | 0.310 |
Why?
|
Apoptosis | 8 | 2021 | 9468 | 0.290 |
Why?
|
Myeloid Cells | 2 | 2023 | 820 | 0.290 |
Why?
|
Lymphocyte Activation | 1 | 2018 | 5490 | 0.290 |
Why?
|
Neoplasms | 6 | 2023 | 22030 | 0.280 |
Why?
|
Lung Neoplasms | 2 | 2024 | 13245 | 0.270 |
Why?
|
Immunity, Innate | 3 | 2019 | 3046 | 0.260 |
Why?
|
bcl-X Protein | 2 | 2019 | 411 | 0.260 |
Why?
|
T-Lymphocytes | 2 | 2021 | 10171 | 0.240 |
Why?
|
Cyclophosphamide | 1 | 2008 | 2218 | 0.210 |
Why?
|
Antineoplastic Agents | 4 | 2019 | 13591 | 0.200 |
Why?
|
Phagocytosis | 2 | 2018 | 1533 | 0.190 |
Why?
|
Transplantation, Isogeneic | 1 | 2021 | 248 | 0.190 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 6 | 2023 | 11709 | 0.180 |
Why?
|
Antibodies, Bispecific | 1 | 2023 | 191 | 0.180 |
Why?
|
Ketones | 1 | 2021 | 183 | 0.180 |
Why?
|
Furans | 1 | 2021 | 199 | 0.180 |
Why?
|
Professional-Family Relations | 2 | 2021 | 495 | 0.180 |
Why?
|
Allergy and Immunology | 1 | 2021 | 175 | 0.170 |
Why?
|
DNA-Directed DNA Polymerase | 1 | 2023 | 489 | 0.170 |
Why?
|
CD8-Positive T-Lymphocytes | 4 | 2023 | 4549 | 0.170 |
Why?
|
Death Domain Receptor Signaling Adaptor Proteins | 1 | 2019 | 33 | 0.160 |
Why?
|
Mammary Glands, Animal | 1 | 2020 | 271 | 0.160 |
Why?
|
Mice | 14 | 2024 | 81107 | 0.160 |
Why?
|
Neoplasm Transplantation | 2 | 2021 | 2013 | 0.160 |
Why?
|
Caregivers | 2 | 2021 | 2224 | 0.160 |
Why?
|
Animals | 18 | 2024 | 167777 | 0.150 |
Why?
|
Health Communication | 1 | 2021 | 213 | 0.150 |
Why?
|
Pyrimidinones | 1 | 2020 | 383 | 0.150 |
Why?
|
Monoclonal Gammopathy of Undetermined Significance | 1 | 2020 | 179 | 0.150 |
Why?
|
Macrophage Activation | 2 | 2020 | 552 | 0.150 |
Why?
|
Seizures | 2 | 2021 | 2919 | 0.150 |
Why?
|
Receptors, Immunologic | 1 | 2024 | 1411 | 0.150 |
Why?
|
Cisplatin | 2 | 2020 | 1645 | 0.140 |
Why?
|
Humans | 43 | 2024 | 758381 | 0.140 |
Why?
|
Oxadiazoles | 1 | 2017 | 94 | 0.140 |
Why?
|
Necrosis | 3 | 2011 | 1604 | 0.140 |
Why?
|
BRCA1 Protein | 2 | 2020 | 1147 | 0.140 |
Why?
|
Parents | 2 | 2021 | 3548 | 0.140 |
Why?
|
Urothelium | 1 | 2019 | 277 | 0.140 |
Why?
|
Xenograft Model Antitumor Assays | 5 | 2020 | 3574 | 0.130 |
Why?
|
Drug Synergism | 2 | 2017 | 1745 | 0.130 |
Why?
|
Apoptosis Regulatory Proteins | 2 | 2019 | 1134 | 0.130 |
Why?
|
Infant, Newborn, Diseases | 1 | 2021 | 592 | 0.130 |
Why?
|
Neoplasm Metastasis | 3 | 2021 | 4901 | 0.130 |
Why?
|
Paclitaxel | 5 | 2023 | 1728 | 0.120 |
Why?
|
Stromal Cells | 1 | 2020 | 1326 | 0.120 |
Why?
|
Immunologic Factors | 2 | 2021 | 1585 | 0.120 |
Why?
|
Estrogen Receptor alpha | 1 | 2019 | 580 | 0.120 |
Why?
|
Neoadjuvant Therapy | 3 | 2023 | 2821 | 0.120 |
Why?
|
Mice, Nude | 3 | 2011 | 3602 | 0.120 |
Why?
|
Adaptive Immunity | 1 | 2019 | 726 | 0.120 |
Why?
|
Hydroxamic Acids | 1 | 2017 | 481 | 0.120 |
Why?
|
Gene Expression Profiling | 3 | 2021 | 9405 | 0.110 |
Why?
|
Female | 23 | 2024 | 390316 | 0.110 |
Why?
|
Membrane Glycoproteins | 1 | 2024 | 3705 | 0.110 |
Why?
|
Drug Administration Schedule | 1 | 2021 | 4839 | 0.110 |
Why?
|
Antigens, CD | 1 | 2023 | 3997 | 0.110 |
Why?
|
Ovarian Neoplasms | 2 | 2019 | 4876 | 0.100 |
Why?
|
Carcinoma, Pancreatic Ductal | 1 | 2023 | 1724 | 0.100 |
Why?
|
Multiple Myeloma | 3 | 2020 | 5129 | 0.100 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2016 | 494 | 0.100 |
Why?
|
Colorectal Neoplasms | 2 | 2022 | 6852 | 0.090 |
Why?
|
Benzamides | 1 | 2017 | 1368 | 0.090 |
Why?
|
Tumor Burden | 1 | 2017 | 1893 | 0.090 |
Why?
|
Cell Proliferation | 4 | 2021 | 10417 | 0.090 |
Why?
|
Class Ia Phosphatidylinositol 3-Kinase | 1 | 2010 | 76 | 0.090 |
Why?
|
Pyrazoles | 1 | 2020 | 1990 | 0.090 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2020 | 2825 | 0.090 |
Why?
|
Cell Differentiation | 2 | 2018 | 11471 | 0.090 |
Why?
|
Molecular Targeted Therapy | 2 | 2019 | 2796 | 0.090 |
Why?
|
Cell Line, Transformed | 1 | 2011 | 869 | 0.080 |
Why?
|
Serpins | 1 | 2011 | 247 | 0.080 |
Why?
|
Adaptation, Psychological | 1 | 2020 | 2629 | 0.080 |
Why?
|
Adenovirus E1A Proteins | 1 | 2008 | 73 | 0.080 |
Why?
|
Evidence-Based Medicine | 1 | 2021 | 3671 | 0.080 |
Why?
|
Mice, Transgenic | 1 | 2021 | 9518 | 0.080 |
Why?
|
bcl-2 Homologous Antagonist-Killer Protein | 1 | 2008 | 71 | 0.080 |
Why?
|
Epithelial Cells | 1 | 2020 | 3665 | 0.080 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2015 | 1404 | 0.080 |
Why?
|
Peptides | 2 | 2024 | 4341 | 0.080 |
Why?
|
Fibroblasts | 2 | 2016 | 4087 | 0.080 |
Why?
|
Colonic Neoplasms | 1 | 2020 | 2523 | 0.080 |
Why?
|
Genome, Human | 2 | 2021 | 4415 | 0.070 |
Why?
|
bcl-2-Associated X Protein | 1 | 2008 | 282 | 0.070 |
Why?
|
Cytokines | 2 | 2021 | 7338 | 0.070 |
Why?
|
Random Allocation | 1 | 2011 | 2385 | 0.070 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2019 | 2276 | 0.070 |
Why?
|
Genes, ras | 1 | 2008 | 654 | 0.070 |
Why?
|
Biomedical Research | 1 | 2021 | 3417 | 0.060 |
Why?
|
Carcinoma, Renal Cell | 1 | 2021 | 3217 | 0.060 |
Why?
|
DNA-Binding Proteins | 2 | 2021 | 9575 | 0.060 |
Why?
|
Pancreatic Neoplasms | 1 | 2023 | 5349 | 0.060 |
Why?
|
Lung | 1 | 2024 | 9985 | 0.060 |
Why?
|
Clinical Trials as Topic | 1 | 2021 | 7985 | 0.060 |
Why?
|
Pyrimidines | 1 | 2017 | 3006 | 0.060 |
Why?
|
Signal Transduction | 3 | 2021 | 23341 | 0.060 |
Why?
|
Taxoids | 1 | 2008 | 668 | 0.060 |
Why?
|
Stress, Psychological | 1 | 2020 | 4457 | 0.060 |
Why?
|
HEK293 Cells | 2 | 2011 | 4258 | 0.060 |
Why?
|
Kidney Neoplasms | 1 | 2021 | 4312 | 0.060 |
Why?
|
Genomics | 4 | 2021 | 5789 | 0.060 |
Why?
|
Physicians | 1 | 2021 | 4581 | 0.050 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2019 | 8506 | 0.050 |
Why?
|
DNA, Neoplasm | 1 | 2008 | 1745 | 0.050 |
Why?
|
Cells, Cultured | 3 | 2020 | 18942 | 0.050 |
Why?
|
Antigens, Neoplasm | 1 | 2011 | 1997 | 0.050 |
Why?
|
Gene Expression Regulation | 1 | 2020 | 11894 | 0.050 |
Why?
|
Autophagy | 1 | 2010 | 1322 | 0.050 |
Why?
|
Membrane Proteins | 1 | 2019 | 7843 | 0.050 |
Why?
|
Aging | 1 | 2020 | 8651 | 0.050 |
Why?
|
Treatment Outcome | 4 | 2021 | 64379 | 0.050 |
Why?
|
Antibodies, Monoclonal | 1 | 2018 | 9160 | 0.050 |
Why?
|
Qualitative Research | 2 | 2021 | 2976 | 0.040 |
Why?
|
Disease Models, Animal | 2 | 2017 | 18125 | 0.040 |
Why?
|
Risk Assessment | 1 | 2021 | 23883 | 0.040 |
Why?
|
Single-Cell Analysis | 2 | 2020 | 2379 | 0.040 |
Why?
|
Time Factors | 1 | 2021 | 39873 | 0.040 |
Why?
|
Nuclear Family | 1 | 2020 | 313 | 0.040 |
Why?
|
Atlases as Topic | 1 | 2020 | 241 | 0.040 |
Why?
|
Nucleotides, Cyclic | 1 | 2019 | 84 | 0.040 |
Why?
|
DNA Damage | 1 | 2008 | 2439 | 0.040 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 5246 | 0.040 |
Why?
|
Prospective Studies | 5 | 2023 | 54136 | 0.040 |
Why?
|
Genetic Heterogeneity | 1 | 2021 | 723 | 0.040 |
Why?
|
Prognosis | 4 | 2021 | 29558 | 0.040 |
Why?
|
Disease Progression | 4 | 2019 | 13468 | 0.040 |
Why?
|
Object Attachment | 1 | 2020 | 326 | 0.040 |
Why?
|
Risk Factors | 2 | 2022 | 73806 | 0.040 |
Why?
|
Antibody-Dependent Cell Cytotoxicity | 1 | 2018 | 303 | 0.030 |
Why?
|
Microsatellite Instability | 1 | 2020 | 715 | 0.030 |
Why?
|
Burns | 1 | 2008 | 1848 | 0.030 |
Why?
|
Genes, Tumor Suppressor | 1 | 2020 | 1055 | 0.030 |
Why?
|
Carboplatin | 1 | 2019 | 788 | 0.030 |
Why?
|
Antigen Presentation | 1 | 2021 | 1254 | 0.030 |
Why?
|
Octamer Transcription Factor-3 | 1 | 2016 | 223 | 0.030 |
Why?
|
Male | 10 | 2021 | 358742 | 0.030 |
Why?
|
Uncertainty | 1 | 2020 | 751 | 0.030 |
Why?
|
Cytochromes c | 1 | 2015 | 173 | 0.030 |
Why?
|
Estrogens | 1 | 2021 | 1520 | 0.030 |
Why?
|
Loss of Heterozygosity | 1 | 2016 | 659 | 0.030 |
Why?
|
BRCA2 Protein | 1 | 2019 | 798 | 0.030 |
Why?
|
Parenting | 1 | 2020 | 695 | 0.030 |
Why?
|
Health Care Surveys | 1 | 2021 | 2432 | 0.030 |
Why?
|
Interleukin-10 | 1 | 2019 | 1174 | 0.030 |
Why?
|
Teratoma | 1 | 2016 | 403 | 0.030 |
Why?
|
Middle Aged | 7 | 2023 | 219560 | 0.030 |
Why?
|
Phenotype | 2 | 2021 | 16534 | 0.030 |
Why?
|
Aged | 6 | 2023 | 168217 | 0.030 |
Why?
|
Lymphocytes | 1 | 2020 | 2610 | 0.030 |
Why?
|
Mitochondria | 2 | 2016 | 3584 | 0.030 |
Why?
|
Transcription Factors | 2 | 2023 | 12096 | 0.030 |
Why?
|
Histone Deacetylases | 1 | 2017 | 719 | 0.030 |
Why?
|
Biological Assay | 1 | 2015 | 626 | 0.030 |
Why?
|
Mutation | 3 | 2024 | 29915 | 0.030 |
Why?
|
Sequence Analysis, RNA | 1 | 2020 | 2001 | 0.030 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2020 | 3527 | 0.020 |
Why?
|
Leadership | 1 | 2021 | 1371 | 0.020 |
Why?
|
Plasma Cells | 1 | 2015 | 591 | 0.020 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2020 | 2416 | 0.020 |
Why?
|
Fear | 1 | 2020 | 1462 | 0.020 |
Why?
|
Class III Phosphatidylinositol 3-Kinases | 1 | 2010 | 17 | 0.020 |
Why?
|
Infant, Newborn | 2 | 2021 | 26182 | 0.020 |
Why?
|
Organ Specificity | 1 | 2015 | 1955 | 0.020 |
Why?
|
Testicular Neoplasms | 1 | 2016 | 801 | 0.020 |
Why?
|
Phosphatidylinositol Phosphates | 1 | 2010 | 202 | 0.020 |
Why?
|
Aniline Compounds | 1 | 2015 | 1068 | 0.020 |
Why?
|
Antibodies, Neoplasm | 1 | 2011 | 280 | 0.020 |
Why?
|
Dendritic Cells | 1 | 2020 | 2723 | 0.020 |
Why?
|
Phagosomes | 1 | 2010 | 199 | 0.020 |
Why?
|
Tissue Array Analysis | 1 | 2011 | 551 | 0.020 |
Why?
|
Phylogeny | 1 | 2016 | 2774 | 0.020 |
Why?
|
Cell Cycle Proteins | 1 | 2020 | 3443 | 0.020 |
Why?
|
Adaptor Proteins, Vesicular Transport | 1 | 2010 | 306 | 0.020 |
Why?
|
Patient Care Team | 1 | 2020 | 2504 | 0.020 |
Why?
|
Killer Cells, Natural | 1 | 2018 | 2201 | 0.020 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2016 | 1725 | 0.020 |
Why?
|
Nuclear Proteins | 1 | 2023 | 5787 | 0.020 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2020 | 3615 | 0.020 |
Why?
|
Evolution, Molecular | 1 | 2016 | 1885 | 0.020 |
Why?
|
Biopolymers | 1 | 2008 | 184 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2019 | 8530 | 0.020 |
Why?
|
Survival Rate | 1 | 2021 | 12721 | 0.020 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2019 | 4353 | 0.020 |
Why?
|
Survival Analysis | 1 | 2019 | 10112 | 0.020 |
Why?
|
Early Detection of Cancer | 1 | 2021 | 3211 | 0.020 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2016 | 2912 | 0.020 |
Why?
|
Adult | 4 | 2021 | 219916 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2020 | 12440 | 0.020 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2008 | 714 | 0.020 |
Why?
|
Sulfonamides | 1 | 2015 | 1973 | 0.020 |
Why?
|
Immunohistochemistry | 1 | 2019 | 11070 | 0.020 |
Why?
|
Anxiety | 1 | 2020 | 4538 | 0.020 |
Why?
|
Immunoenzyme Techniques | 1 | 2008 | 1705 | 0.020 |
Why?
|
Smoking | 1 | 2022 | 9042 | 0.020 |
Why?
|
Embryo, Mammalian | 1 | 2010 | 1674 | 0.010 |
Why?
|
Tubulin | 1 | 2008 | 692 | 0.010 |
Why?
|
Incidence | 1 | 2022 | 21273 | 0.010 |
Why?
|
Recurrence | 1 | 2015 | 8426 | 0.010 |
Why?
|
Drug Design | 1 | 2008 | 1049 | 0.010 |
Why?
|
Point Mutation | 1 | 2008 | 1593 | 0.010 |
Why?
|
Structure-Activity Relationship | 1 | 2008 | 3069 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2020 | 22006 | 0.010 |
Why?
|
Recombinant Fusion Proteins | 1 | 2010 | 3734 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2010 | 2443 | 0.010 |
Why?
|
Disease-Free Survival | 1 | 2011 | 6821 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2022 | 39060 | 0.010 |
Why?
|
Enzyme Inhibitors | 1 | 2010 | 3709 | 0.010 |
Why?
|
Transplantation, Heterologous | 1 | 2008 | 2378 | 0.010 |
Why?
|
Ischemia | 1 | 2008 | 1863 | 0.010 |
Why?
|
Infant | 1 | 2021 | 36054 | 0.010 |
Why?
|
Quality of Life | 1 | 2020 | 13286 | 0.010 |
Why?
|
Child, Preschool | 1 | 2021 | 42058 | 0.010 |
Why?
|
Heart | 1 | 2010 | 4382 | 0.010 |
Why?
|
Rats, Sprague-Dawley | 1 | 2008 | 8144 | 0.010 |
Why?
|
Biopsy | 1 | 2008 | 6768 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2011 | 11152 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2010 | 14354 | 0.010 |
Why?
|
Liver | 1 | 2010 | 7502 | 0.010 |
Why?
|
Pilot Projects | 1 | 2008 | 8554 | 0.010 |
Why?
|
Skin | 1 | 2008 | 4464 | 0.010 |
Why?
|
Young Adult | 1 | 2020 | 58808 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2011 | 20052 | 0.010 |
Why?
|
United States | 1 | 2020 | 72140 | 0.010 |
Why?
|
Rats | 1 | 2008 | 23681 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2015 | 58681 | 0.010 |
Why?
|